Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 5/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215050 | 0.92 | RXRA (0.47) | RXRALTC4SPDE4BPDE4APDE4C | |
| SCHEMBL3218504 | 0.91 | LTC4S (0.46) | RXRALTC4SPDE4BPDE4APDE4C | |
| SCHEMBL3192176 | 0.89 | PDE4B (0.37) | RXRALTC4SPDE4BPDE4APDE4C | |
| SCHEMBL3205308 | 0.87 | PDE4B (0.43) | RXRAPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3203551 | 0.84 | PDE4B (0.42) | RXRAPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3212603 | 0.83 | PDE4B (0.39) | RXRALTC4SPDE4BPDE4APDE4C | |
| SCHEMBL3201558 | 0.81 | BRD4 (0.38) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3241347 | 0.81 | SLC6A9 (0.41) | RXRAPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3205291 | 0.81 | PDE4B (0.49) | RXRAPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3211820 | 0.80 | CA12 (0.45) | RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | claimed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | RXRA 2856/4885LTC4S 1051/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.